225 related articles for article (PubMed ID: 20084161)
21. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
22. FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.
Mohelnikova-Duchonova B; Melichar B; Soucek P
World J Gastroenterol; 2014 Aug; 20(30):10316-30. PubMed ID: 25132748
[TBL] [Abstract][Full Text] [Related]
23. [Targeted biotherapy: a revolution in the management of patients with colorectal cancer?].
Rougier P; Mitry E
Gastroenterol Clin Biol; 2009; 33(8-9):672-80. PubMed ID: 19717258
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?
Perera MA; Innocenti F; Ratain MJ
Pharmacotherapy; 2008 Jun; 28(6):755-68. PubMed ID: 18503403
[TBL] [Abstract][Full Text] [Related]
25. Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies.
McLeod HL; King CR; Marsh S
Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S43-7. PubMed ID: 15212705
[TBL] [Abstract][Full Text] [Related]
26. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
Innocenti F; Ratain MJ
Pharmacogenomics; 2006 Dec; 7(8):1211-21. PubMed ID: 17184208
[TBL] [Abstract][Full Text] [Related]
28. Systemic therapy for pancreatic cancer.
Ko AH; Tempero MA
Semin Radiat Oncol; 2005 Oct; 15(4):245-53. PubMed ID: 16183478
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
30. [Molecular biology in clinical cancer research: the example of digestive cancers].
Lièvre A; Laurent-Puig P
Rev Epidemiol Sante Publique; 2005 Jun; 53(3):267-82. PubMed ID: 16227914
[TBL] [Abstract][Full Text] [Related]
31. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
Burris H; Rocha-Lima C
Oncologist; 2008 Mar; 13(3):289-98. PubMed ID: 18378539
[TBL] [Abstract][Full Text] [Related]
32. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
Seymour MT; Brown SR; Middleton G; Maughan T; Richman S; Gwyther S; Lowe C; Seligmann JF; Wadsley J; Maisey N; Chau I; Hill M; Dawson L; Falk S; O'Callaghan A; Benstead K; Chambers P; Oliver A; Marshall H; Napp V; Quirke P
Lancet Oncol; 2013 Jul; 14(8):749-59. PubMed ID: 23725851
[TBL] [Abstract][Full Text] [Related]
33. New oxaliplatin-based combinations in the treatment of colorectal cancer.
Cassidy J; Hochster H
Colorectal Dis; 2003 Nov; 5 Suppl 3():1-9. PubMed ID: 23573555
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy.
Fujita K; Sasaki Y
Curr Drug Metab; 2007 Aug; 8(6):554-62. PubMed ID: 17691917
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
Denlinger CS; Blanchard R; Xu L; Bernaards C; Litwin S; Spittle C; Berg DJ; McLaughlin S; Redlinger M; Dorr A; Hambleton J; Holden S; Kearns A; Kenkare-Mitra S; Lum B; Meropol NJ; O'Dwyer PJ
Cancer Chemother Pharmacol; 2009 Dec; 65(1):97-105. PubMed ID: 19415281
[TBL] [Abstract][Full Text] [Related]
36. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Giusti RM; Shastri K; Pilaro AM; Fuchs C; Cordoba-Rodriguez R; Koti K; Rothmann M; Men AY; Zhao H; Hughes M; Keegan P; Weiss KD; Pazdur R
Clin Cancer Res; 2008 Mar; 14(5):1296-302. PubMed ID: 18316547
[TBL] [Abstract][Full Text] [Related]
37. Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy.
Matasar MJ; Sundararajan V; Grann VR; Neugut AI
Drugs Aging; 2004; 21(2):113-33. PubMed ID: 14960128
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
[TBL] [Abstract][Full Text] [Related]
39. Irinotecan decreases intestinal UDP-glucuronosyltransferase (UGT) 1A1 via TLR4/MyD88 pathway prior to the onset of diarrhea.
Tao G; Dagher F; Li L; Singh R; Hu M; Ghose R
Food Chem Toxicol; 2022 Aug; 166():113246. PubMed ID: 35728726
[TBL] [Abstract][Full Text] [Related]
40. [A perspective: role of targeted therapy in colon cancer].
Chung HH; Jang BI
Korean J Gastroenterol; 2013 Mar; 61(3):128-35. PubMed ID: 23575231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]